(SNDX) Syndax Pharmaceuticals - Ratings and Ratios

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that focuses on developing innovative therapies for cancer treatment. The companys pipeline includes several promising candidates, such as Revuforj (revumenib), a menin inhibitor targeting relapsed or refractory acute leukemia, and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody for chronic graft-versus-host disease. Revumenib is also being explored for its potential in treating R/R acute myeloid leukemia with a nucleophosmin1 mutation and metastatic colorectal cancer.

Syndax is also advancing its research in other areas, including the use of axatilimab for idiopathic pulmonary fibrosis and Entinostat, a Class1 HDAC inhibitor. The company has partnered with Eddingpharm International Company Limited for the licensing, development, and commercialization of Entinostat, demonstrating its commitment to collaborative efforts to bring new treatments to market. With a strong foundation established since its incorporation in 2005, Syndax Pharmaceuticals is headquartered in New York, New York, and continues to push forward with its mission to develop groundbreaking cancer therapies.

From a technical standpoint, SNDX has shown a downward trend, with its last price at $10.25, below its SMA20 and SMA50. The stocks ATR indicates a relatively high volatility of 8.15%. Given the current market conditions and the companys pipeline, a potential support level could be around $8.95, its 52-week low. A break below this level could signal further decline, while a rebound above $11.27 (SMA50) might indicate a reversal in the downtrend.

Fundamentally, Syndax Pharmaceuticals has a market capitalization of $944.80M USD, with a negative P/E ratio indicating that the company is currently not profitable. The lack of a forward P/E ratio suggests that analysts may not have a clear estimate for future earnings. The companys return on equity is significantly negative, highlighting the challenges it faces in generating profits for shareholders. However, the ongoing development of its lead candidates and potential future approvals could be key catalysts for growth.

Forecasting SNDXs future performance involves analyzing both its technical and fundamental data. Given the current downward trend and high volatility, the stock may continue to face challenges in the short term. However, if revumenib or axatilimab show positive results in their ongoing trials, this could lead to a significant increase in the stock price. A potential target could be around $14.93, its SMA200, if the company achieves significant milestones. Conversely, failure to meet clinical trial endpoints or regulatory setbacks could push the stock price lower, potentially towards its 52-week low.